These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12799623)

  • 41. Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast cancer scheduled for high-dose chemotherapy and peripheral blood progenitor cell support.
    Papadopoulos KP; Ayello J; Tugulea S; Heitjan DF; Williams C; Reiss RF; Vahdat LT; Suciu-Foca N; Antman KH; Hesdorffer CS
    J Hematother; 1997 Feb; 6(1):61-8. PubMed ID: 9112219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
    Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy.
    Schrama JG; de Boer MM; Baars JW; Schornagel JH; Rodenhuis S
    Anticancer Res; 2003; 23(3C):2795-800. PubMed ID: 12926115
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I-II study of bialkylator chemotherapy, high-dose thiotepa, and cyclophosphamide with autologous bone marrow reinfusion in patients with advanced cancer.
    Williams SF; Bitran JD; Kaminer L; Westbrook C; Jacobs R; Ashenhurst J; Robin E; Purl S; Beschorner J; Schroeder C
    J Clin Oncol; 1987 Feb; 5(2):260-5. PubMed ID: 3027271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
    van Warmerdam LJ; Rodenhuis S; van der Wall E; Maes RA; Beijnen JH
    Br J Cancer; 1996 Apr; 73(8):979-84. PubMed ID: 8611435
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.
    Antman K; Ayash L; Elias A; Wheeler C; Hunt M; Eder JP; Teicher BA; Critchlow J; Bibbo J; Schnipper LE
    J Clin Oncol; 1992 Jan; 10(1):102-10. PubMed ID: 1727912
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
    Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
    Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients.
    Bachelot T; Gomez F; Biron P; Ray-Coquard I; Soler-Michel P; Philip I; Guastalla JP; Rebattu P; Dumortier A; Droz JP; Blay JY
    Br J Cancer; 2002 Nov; 87(10):1079-85. PubMed ID: 12402145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 53. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity.
    Motzer RJ; Mazumdar M; Bosl GJ; Bajorin DF; Amsterdam A; Vlamis V
    J Clin Oncol; 1996 Apr; 14(4):1098-105. PubMed ID: 8648363
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer.
    Crown J; Kritz A; Vahdat L; Reich L; Moore M; Hamilton N; Schneider J; Harrison M; Gilewski T; Hudis C
    J Clin Oncol; 1993 Jun; 11(6):1144-9. PubMed ID: 7684770
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer.
    Rodenhuis S; van der Wall E; ten Bokkel Huinink WW; Schornagel JH; Richel DJ; Vlasveld LT
    Cancer Invest; 1995; 13(4):355-62. PubMed ID: 7627721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
    Papadopoulos KP; Garvin JH; Fetell M; Vahdat LT; Garrett TJ; Savage DG; Balmaceda C; Bruce J; Sisti M; Isaacson S; De LaPaz R; Hawks R; Bagiella E; Antman KH; Hesdorffer CS
    Bone Marrow Transplant; 1998 Oct; 22(7):661-7. PubMed ID: 9818693
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
    de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
    Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
    van Maanen MJ; Huitema AD; Rodenhuis S; Beijnen JH
    Anticancer Drugs; 2001 Jul; 12(6):519-24. PubMed ID: 11459998
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumor patients.
    Eder JP; Elias A; Shea TC; Schryber SM; Teicher BA; Hunt M; Burke J; Siegel R; Schnipper LE; Frei E
    J Clin Oncol; 1990 Jul; 8(7):1239-45. PubMed ID: 2162912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.
    Stemmer SM; Pfeffer MR; Rizel S; Hardan I; Goffman J; Gezin A; Neumann A; Kitsios P; Alezra D; Brenner HJ
    Cancer; 2001 Jun; 91(11):1983-91. PubMed ID: 11391576
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.